Kliniske studier for Overvekt i Nevada
24 studier for Overvekt søker deltakere på steder i Nevada.
Byer i Nevada
Offisiell studietekst (engelsk)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Vector Clinical Trials /ID# 282265, Las Vegas
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07752979AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Palm Research Center Inc., Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07720271A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- M3 Wake Research - Las Vegas Cimarron, Las Vegas
- Renascor Clinical Research, Reno
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07794579A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07776509A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Palm Research Center Tenaya, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07369011Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Excel Clinical Research, Las Vegas
- Vector Clinical Trials, Las Vegas
RekruttererFase 3
Alder 45 til 99 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Las Vegas Medical Research, Las Vegas
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT07743450A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Las Vegas
RekruttererFase 3Frivillige helsepersonell ønskes velkommen
Alder 18 til 79 · Alle kjønn · Oppdatert 11. sep. 2026 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Jubilee Clinical Research, Inc., Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07770841A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Las Vegas Medical Research, Las Vegas
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06143956A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Vector Clinical Trials, Las Vegas
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07215559A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Skin Cancer and Dermatology Institute - Reno, Reno
RekruttererFase 4
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Palm Research Center Inc, Las Vegas
- Vector Clinical Trials, Las Vegas
RekruttererFase 3
Alder 18 til 99 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Palm Research Center Inc, Las Vegas
RekruttererFase 3
Alder 18 til 99 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07684144Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Excel Clinical Research, Las Vegas
RekruttererFase 3
Alder 18 til 99 · Alle kjønn · Oppdatert 27. aug. 2026 · NCT07575399Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.
- University of Nevada, Las Vegas, Las Vegas
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 21 til 74 · Alle kjønn · Oppdatert 27. aug. 2026 · NCT07566325A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Las Vegas
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Las Vegas
RekruttererFase 3
Alder 18 til 79 · Alle kjønn · Oppdatert 10. aug. 2026 · NCT07654361A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
- Corxel Investigational site, Las Vegas
RekruttererFase 1
Alder 18 til 55 · Kvinner · Oppdatert 17. jun. 2026 · NCT07652047Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.